long intergenic non-protein coding RNA 2159Genealiases: []
Q-omics provides the consensus-scored LINC02159 profile across patient tissues and cancer cell-line models. LINC02159 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, LINC02159 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LINC02159 RNA expression shows 10,323 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight COAD, KIRC, and TGCT as cancer lineages where LINC02159 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02159 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02159 survival associations across molecular data types. LINC02159 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02159 RNA expression–survival associations across cancer types. High LINC02159 expression shows unfavorable associations in BRCA, STAD and LUAD, but favorable associations in COAD, LUSC and HNSC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for LINC02159 RNA expression.
This table summarizes LINC02159 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02159. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02159 shows lower tumor expression in KIRC and KIRP and higher tumor expression in LUAD, LUSC, UCEC and THCA. The KIRC box plot shows higher LINC02159 RNA expression in normal versus tumor tissue (log2 FC = −0.676, t-test p < 0.001).
This table shows molecular features associated with LINC02159 in patient tissues and cancer cell lines. In patient samples, LINC02159 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
